Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:03:57.775Z.
Calculation as of: 2026-10-06T20:03:57.775Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$218.30M
Price/FCF Ratio
N/A
TTM Avg
9.31
3Y Avg
9.38
5Y Avg
9.38
Market Cap
$216.91M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$225.24M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
Price/FCF Ratio
37.76
TTM Avg
48.24
3Y Avg
64.03
5Y Avg
64.30
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $220.93M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A | 9.31 | 9.38 | 9.38 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 37.76 | 48.24 | 64.03 | 64.30 |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
